BioArctic AB (BIOA B) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Swedish Orphan Biovitrum AB

BioArctic AB

Swedencare AB

Camurus AB

Calliditas Therapeutics AB

Egetis Therapeutics AB

Hansa Biopharma AB

Vicore Pharma Holding AB

Xspray Pharma AB

Infant Bacterial Therapeutics AB

FluoGuide A/S

Why is BioArctic AB ?

High Management Efficiency with a high ROE of 15.35%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of -8.97

Healthy long term growth as Net Sales has grown by an annual rate of 100.08% and Operating profit at 78.36%

Negative results in Dec 25

NET SALES(Q) At SEK 184.04 MM has Fallen at -61.59%
PRE-TAX PROFIT(Q) At SEK 39.07 MM has Fallen at -86.67%
NET PROFIT(Q) At SEK -8.83 MM has Fallen at -103.53%

With ROE of 52.40%, it has a fair valuation with a 13.23 Price to Book Value

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 76.91%, its profits have risen by 1308.6% ; the PEG ratio of the company is 0

Majority shareholders : Non Institution

Market Beating Performance

The stock has generated a return of 76.91% in the last 1 year, much higher than market (OMX Stockholm 30) returns of 10.97%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to BioArctic AB should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is BioArctic AB for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

BioArctic AB

76.91%

0.71

52.14%

OMX Stockholm 30

10.97%

0.59

18.59%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

100.08%

EBIT Growth (5y)

78.36%

EBIT to Interest (avg)

-8.97

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.28

Sales to Capital Employed (avg)

0.58

Tax Ratio

3.43%

Dividend Payout Ratio

17.32%

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

17.86%

ROE (avg)

15.35%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

13.23

EV to EBIT

19.58

EV to EBITDA

19.58

EV to Capital Employed

186.26

EV to Sales

13.46

PEG Ratio

0.02

Dividend Yield

ROCE (Latest)

951.43%

ROE (Latest)

52.40%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

15What is working for the Company

NET PROFIT(9M)

At SEK 0.85 MM has Grown at 100.71%

OPERATING CASH FLOW(Y)

Highest at SEK 1,431.06 MM

NET SALES(HY)

At SEK 317.38 MM has Grown at 78.44%

RAW MATERIAL COST(Y)

Fallen by -4.03% (YoY

CASH AND EQV(HY)

Highest at SEK 4,072.39 MM

DEBT-EQUITY RATIO (HY)

Lowest at -109.11 %

DIVIDEND PER SHARE(HY)

Highest at SEK 0

-23What is not working for the Company

NET SALES(Q)

At SEK 184.04 MM has Fallen at -61.59%

PRE-TAX PROFIT(Q)

At SEK 39.07 MM has Fallen at -86.67%

NET PROFIT(Q)

At SEK -8.83 MM has Fallen at -103.53%

INTEREST(Q)

At SEK 4.93 MM has Grown at 85.1%

Here's what is working for BioArctic AB

Operating Cash Flow

Highest at SEK 1,431.06 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (SEK MM)

Cash and Eqv

Highest at SEK 4,072.39 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -109.11 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Dividend per share

Highest at SEK 0

in the last five years

MOJO Watch

Company is distributing higher dividend from profits generated

DPS (SEK)

Raw Material Cost

Fallen by -4.03% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for BioArctic AB

Net Sales

At SEK 184.04 MM has Fallen at -61.59%

over average net sales of the previous four periods of SEK 479.08 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (SEK MM)

Pre-Tax Profit

At SEK 39.07 MM has Fallen at -86.67%

over average net sales of the previous four periods of SEK 293.15 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (SEK MM)

Net Profit

At SEK -8.83 MM has Fallen at -103.53%

over average net sales of the previous four periods of SEK 249.92 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (SEK MM)

Interest

At SEK 4.93 MM has Grown at 85.1%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (SEK MM)